Levosimendan in High Risk Patients Undergoing Cardiac Surgery (HSR-LEVO)


Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial

Low cardiac output syndrome (LCOs) is a serious complication in critically ill patients or those undergoing major surgery, resulting in multiple organ damage with significant in-hospital and long-term morbidity and mortality, as well as prolonged hospital stay. In this setting the mortality rate is distressingly high despite improvements in intensive care treatment, but survivors have an acceptable quality of life.

Are you Eligible? (Inclusion Criteria)

  • Written informed consent
  • Age > 18 years
  • Perioperative myocardial dysfunction

Specialty Area(s)

Trial Location

Columbia University Medical Center
New York, NY 10032
United States